Premium
Singapore state investor Temasek Holdings is staring at a sharp loss from its nearly five-year-old investment in an Indian drugmaker that has been selling assets to pare its debt. Temasek is likely to get back just half the money it had poured in Glenmark Pharmaceuticals Ltd, according to information pieced together ......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a selection of our recent premium content.
Already a member? Click here to log in.
